ResMed Fair value decreased by 41.3% to $5.48M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 54.9%, from $12.13M to $5.48M. Over 4 years (FY 2021 to FY 2025), Fair value shows a downward trend with a -18.1% CAGR.
other_marketable_equity_investments_fair_value| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $29.08M | $33.14M | $19.57M | $17.84M | $9.17M | $5.89M | $4.98M | $12.12M | $12.42M | $11.82M | $7.62M | $21.54M | $12.03M | $16.22M | $14.78M | $12.13M | $13.08M | $8.02M | $9.32M | $5.48M |
| QoQ Change | — | +13.9% | -41.0% | -8.8% | -48.6% | -35.8% | -15.4% | +143.3% | +2.5% | -4.8% | -35.6% | +182.7% | -44.2% | +34.8% | -8.9% | -17.9% | +7.8% | -38.7% | +16.3% | -41.3% |
| YoY Change | — | — | — | — | -68.5% | -82.2% | -74.5% | -32.1% | +35.5% | +100.8% | +53.0% | +77.8% | -3.2% | +37.2% | +94.0% | -43.7% | +8.8% | -50.6% | -36.9% | -54.9% |